Gastroenteritis Rehydration Of children with Severe Acute Malnutrition (GASTROSAM): A Phase II Randomised Controlled trial: Trial Protocol.

African Children Dehydration Gastroenteritis Intravenous fluids Rehydration Severe Malnutrition WHO guidelines

Journal

Wellcome open research
ISSN: 2398-502X
Titre abrégé: Wellcome Open Res
Pays: England
ID NLM: 101696457

Informations de publication

Date de publication:
2021
Historique:
accepted: 02 11 2023
medline: 22 7 2021
pubmed: 22 7 2021
entrez: 18 1 2024
Statut: epublish

Résumé

Children hospitalised with severe acute malnutrition (SAM) are frequently complicated (>50%) by diarrhoea ( ≥3 watery stools/day) which is accompanied by poor outcomes. Rehydration guidelines for SAM are exceptionally conservative and controversial, based upon expert opinion. The guidelines only permit use of intravenous fluids for cases with advanced shock and exclusive use of low sodium intravenous and oral rehydration solutions (ORS) for fear of fluid and/or sodium overload. Children managed in accordance to these guidelines have a very high mortality. The proposed GASTROSAM trial will reappraise current recommendations with mortality as the primary outcome. We hypothesize that liberal rehydration strategies for both intravenous and oral rehydration in SAM children with diarrhoea may reduce adverse outcomes. An open Phase II trial, with a partial factorial design, enrolling children in Uganda, Kenya, Nigeria and Niger aged 6 months to 12 years with SAM hospitalised with gastroenteritis (>3 loose stools/day) and signs of moderate and severe dehydration. In Stratum A (severe dehydration) children will be randomised (1:1:2) to WHO plan C (100mls/kg Ringers Lactate (RL) with intravenous rehydration (IV) given over 3-6 hours according to age including boluses for shock), slow rehydration (100 mls/kg RL over 8 hours (no boluses)) or WHO SAM rehydration regime (ORS only (boluses for shock (standard of care)). Stratum B incorporates all children with moderate dehydration and severe dehydration post-intravenous rehydration and compares (1:1 ratio) standard WHO ORS given for non-SAM (experimental) versus WHO SAM-recommended low-sodium ReSoMal. The primary outcome for intravenous rehydration is mortality to 96 hours and for oral rehydration a change in sodium levels at 24 hours post-randomisation. Secondary outcomes include measures assessing safety (evidence of pulmonary oedema or heart failure); change in sodium from post-iv levels for those in Stratum A; perturbations of electrolyte abnormalities (severe hyponatraemia <125 mmols/L or hypokalaemia. If the trial shows that rehydration strategies for non-malnourished children are safe and improve mortality in SAM this could prompt revisions to the current treatment recommendations or may prompt future Phase III trials.

Sections du résumé

Background UNASSIGNED
Children hospitalised with severe acute malnutrition (SAM) are frequently complicated (>50%) by diarrhoea ( ≥3 watery stools/day) which is accompanied by poor outcomes. Rehydration guidelines for SAM are exceptionally conservative and controversial, based upon expert opinion. The guidelines only permit use of intravenous fluids for cases with advanced shock and exclusive use of low sodium intravenous and oral rehydration solutions (ORS) for fear of fluid and/or sodium overload. Children managed in accordance to these guidelines have a very high mortality. The proposed GASTROSAM trial will reappraise current recommendations with mortality as the primary outcome. We hypothesize that liberal rehydration strategies for both intravenous and oral rehydration in SAM children with diarrhoea may reduce adverse outcomes.
Methods UNASSIGNED
An open Phase II trial, with a partial factorial design, enrolling children in Uganda, Kenya, Nigeria and Niger aged 6 months to 12 years with SAM hospitalised with gastroenteritis (>3 loose stools/day) and signs of moderate and severe dehydration. In Stratum A (severe dehydration) children will be randomised (1:1:2) to WHO plan C (100mls/kg Ringers Lactate (RL) with intravenous rehydration (IV) given over 3-6 hours according to age including boluses for shock), slow rehydration (100 mls/kg RL over 8 hours (no boluses)) or WHO SAM rehydration regime (ORS only (boluses for shock (standard of care)). Stratum B incorporates all children with moderate dehydration and severe dehydration post-intravenous rehydration and compares (1:1 ratio) standard WHO ORS given for non-SAM (experimental) versus WHO SAM-recommended low-sodium ReSoMal. The primary outcome for intravenous rehydration is mortality to 96 hours and for oral rehydration a change in sodium levels at 24 hours post-randomisation. Secondary outcomes include measures assessing safety (evidence of pulmonary oedema or heart failure); change in sodium from post-iv levels for those in Stratum A; perturbations of electrolyte abnormalities (severe hyponatraemia <125 mmols/L or hypokalaemia.
Discussion UNASSIGNED
If the trial shows that rehydration strategies for non-malnourished children are safe and improve mortality in SAM this could prompt revisions to the current treatment recommendations or may prompt future Phase III trials.

Identifiants

pubmed: 34286105
doi: 10.12688/wellcomeopenres.16885.2
pmc: PMC8276193
doi:

Types de publication

Journal Article

Langues

eng

Pagination

160

Informations de copyright

Copyright: © 2024 Olupot-Olupot P et al.

Déclaration de conflit d'intérêts

No competing interests were disclosed.

Auteurs

Peter Olupot-Olupot (P)

Department of Paediatrics, Mbale Clinical Research Institute, Pallisa Road, Mbale, PO Box 291, Uganda.
Mbale Regional Referral Hospital, Pallisa Road, Mbale, PO Box 291, Uganda.

Florence Aloroker (F)

Department of Paediatrics, Soroti Regional Referral Hospital, Soroti, PO Box 289, Uganda.

Ayub Mpoya (A)

Clinical Trials Facility, KEMRI-Wellcome Trust Research Programme, Kilifi, PO Box 230, Kenya.

Hellen Mnjalla (H)

Clinical Trials Facility, KEMRI-Wellcome Trust Research Programme, Kilifi, PO Box 230, Kenya.

George Paasi (G)

Department of Paediatrics, Mbale Clinical Research Institute, Pallisa Road, Mbale, PO Box 291, Uganda.

Margaret Nakuya (M)

Mbale Regional Referral Hospital, Pallisa Road, Mbale, PO Box 291, Uganda.

Kirsty Houston (K)

Department of Medicine, Imperial College London, London, W2 1PG, UK.

Nchafatso Obonyo (N)

Clinical Trials Facility, KEMRI-Wellcome Trust Research Programme, Kilifi, PO Box 230, Kenya.

Mainga Hamaluba (M)

Clinical Trials Facility, KEMRI-Wellcome Trust Research Programme, Kilifi, PO Box 230, Kenya.

Jennifer A Evans (JA)

Department of Paediatrics, University Hospital of Wales, Cardiff, Wales, CF14 4XW, UK.

Manuel Dewez (M)

Medecins Sans Frontieres, Geneva, Switzerland.

Salifou Atti (S)

Ministry of Public Health, Magaria, Niger.

Ousmane Guindo (O)

Epicentre, Niamey, Niger.

San Maurice Ouattara (SM)

Epicentre, Niamey, Niger.

Abdullahi Chara (A)

MSF OCB, Abuja, Nigeria.

Hadiza Alhaji Sainna (HA)

MSF OCB, Maiduguri, Nigeria.

Omokore Oluseyi Amos (OO)

Child Health Division, Family Health Dept., Federal Ministry of Health, Maiduguri, Nigeria.

Oluwakemi Ogundipe (O)

MSF OCB, Brussels, Belgium.

Temmy Sunyoto (T)

MSF Operational Research Unit, LuxOR, Luxembourg City, Luxembourg.

Celine Langendorf (C)

Epicentre, Paris, France.

Marie-Francoise Scherrer (MF)

Epicentre, Paris, France.

Roberta Petrucci (R)

Medecins Sans Frontieres, Geneva, Switzerland.

Roisin Connon (R)

MRC Clinical Trials Unit at University College London, University College London, London, WC1V 6LJ, UK.

Elizabeth C George (EC)

MRC Clinical Trials Unit at University College London, University College London, London, WC1V 6LJ, UK.

Diana M Gibb (DM)

MRC Clinical Trials Unit at University College London, University College London, London, WC1V 6LJ, UK.

Kathryn Maitland (K)

Clinical Trials Facility, KEMRI-Wellcome Trust Research Programme, Kilifi, PO Box 230, Kenya.
Department of Medicine, Imperial College London, London, W2 1PG, UK.

Classifications MeSH